CRNX Crinetics
- 56.820
- +0.130+0.23%
- 56.820
- 0.0000.00%
Crinetics News
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $77
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $77
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $80
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $80
Optimistic Buy Rating for Crinetics Pharmaceuticals on Paltusotine's Potential and Robust Pipeline
Crinetics Pharmaceuticals Price Target Maintained With a $90.00/Share by Cantor Fitzgerald
Crinetics Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Prothena (PRTA) and Xenon (XENE)
Buy Rating Affirmed for Crinetics Pharmaceuticals on Strong Pipeline and Regulatory Progress
HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $69
Oppenheimer Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)
Buy Rating for Crinetics Pharmaceuticals: Strong Pipeline and Financial Stability
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Elevance Health (ELV) and Johnson & Johnson (JNJ)
JPMorgan Raises Price Target on Crinetics Pharmaceuticals to $54 From $47, Maintains Overweight Rating
Crinetics Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on Crinetics Pharmaceuticals, Raises Price Target to $54
Piper Sandler Maintains Overweight on Crinetics Pharmaceuticals, Maintains $97 Price Target
Analysis
Price Target
No Data
No Data